GlassScriptPhysician profile
Jihad Abialmouna
NPI 1396793782
$18,152.83
in general payments reported to CMS, 2019-2025
50 companies · $2,136 in 2025
The $2,136 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,774 · 2020: $2,950 · 2021: $2,818 · 2022: $3,147 · 2023: $2,186 · 2024: $2,142 · 2025: $2,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,394 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,394.24 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,111.18 | 2019-2025 | |
| Abbvie INC. | $2,072.50 | 2019-2025 | Rinvoq, Vraylar, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $1,953.57 | 2019-2025 | Airsupra, Saphnelo, Breztri |
| Janssen Biotech, INC. | $1,540.09 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,352.16 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Glaxosmithkline, LLC. | $1,137.29 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Lilly USA, LLC | $996.09 | 2019-2025 | Jardiance, Taltz, Mounjaro |
| Mallinckrodt Hospital Products INC. | $939.04 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $834.34 | 2019-2025 | Ofev, Cyltezo |
| Ucb, INC. | $743.70 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $693.73 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $475.54 | 2019-2025 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $347.91 | 2019-2025 | Eliquis, Orencia, Camzyos |
| Exact Sciences Corporation | $307.86 | 2023-2025 | Cologuard Collection Kit |
| Mallinckrodt Enterprises LLC | $271.02 | 2019 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jihad Abialmouna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.